The limitations are the underestimation of the frequency of carriers in families with ovarian cancer and in families with prostate cancer, the non-applicability to ethnic minorities, the impossibility of incorporating third-degree relatives, and non-inclusion of other genes besides BRCA1/BRCA2 [28]. The gene discussed is BRCA2; the disease is ovarian carcinoma.